Hi all
pretty new to all this. I have pumped some into Deltex - looks like a strong product with good growth. Could be a steady gainer.
Does anyone else have this, and anyone have some research on it? Someone with more experience than me!
thanks in advance.
Grajul

Yes good update gm, encouraging re California and also France, just a matter of time.
2517

Can't remember the last time there were No Trades in Deltex for a complete trading day.

On a day when just about all the market is down Deltex are up 50p on low volume, with sells 2 to 1 against buys.
Probably nothing but it does make one wonder.
Hopefully the several weeks of silence is coming to an end, or am I seeing only what I want to see.

Every little helps.

First Round of Companies to Present at AdvaMed 2008 Selected.

Companies selected to make 14-minute presentations at AdvaMed 2008
include:Deltex.
Designed by industry for industry, AdvaMed 2008 is the premier MedTech
conference for business executives, policymakers, media, financiers, and
service providers from around the world. In its inaugural year, AdvaMed
2007 attracted more than 400 organizations and 1,100 industry leaders -
including 300+ CEOs, Presidents and C-level executives.

http://www.emediaworld.com/press_release/release_detail.php?id=115287

After a quiet few weeks/months nice to see another teaching hospital joining the testing group.
The NHS National Technology Adoption Hub ('NTAH') programme. The Manchester Royal Infirmary ('MRI') is one of the three hospitals enrolled in the NATH programme and Deltex Medical today announces that MRI has purchased four CardioQ-ODM monitors to enable it to participate in the NTAH project.

Not yet the big breakthruogh webreakthrough are all waiting for but I don't mind too much as DEMG are moving further forward with each such move as todays announcement.

From The Daily Telegraph, today.

It appears that the NHS is expected to have a 1.75 billion surplus in the bank by the end of this financial year (as thats about 7 months away I'm not sure how they can say this, but still). Also the figures show that there was a surplus of 1.6 billion at the end of the financial year in April.
What a B****Y scandal.
If these figures are true, just think that this could easily pay for the CardioQ to be used in every NHS hospital in the country with plenty of cash left over.
Obviously there are many other good uses this could be put to, but I can't think of many such ways where the pay back would be in many multiples of cash spent.
We all including the NHS except that money spent on the CardioQ reaps benefits of monetary value and the obvious life saving reasons.
So if true re the surplus yet another no brainer for those great minds of the NHS management to get to grips with. Don't hold your breath for a quick decision though.

Good opportunity for Deltex,

US health technology assessment finds no benefit from pulmonary artery catheters

This represents a tremendous market opportunity for Deltex. All clinical trials on ODM have shown benefit. ODM has never caused a patient an adverse event and, as previously announced, ODM was the subject of a highly positive health technology assessment in 2007 which was also commissioned by CMS. The number of patients for whom CMS deemed ODM both reasonable and necessary is estimated to be at least two or three times higher than even the highest estimate of US PAC use.

On the whole very good. Sales up in most areas, losses down.
Still jam tomorrow but at least we are getting a little taster.
As most on here have said, it's sales that matter and I feel that the next 12 months could be make or break for Deltex.
There are many areas that are still pushing at a stiff door but at least these doors are opening abet slowly.
Slow process still but the feeling is there that things are speeding up.
Still feel that once the ball really starts to roll, it will take some stopping, but as said my personal take is that the next 12 months will be fairly critical for Deltex.

Just back from hols and seen the following RNS from 01/10.08.

Nearly 1,000 colorectal surgeons attending the annual meeting of the European Society of Coloproctology in Nantes, France from 24 to 27 September 2008 heard doctors from Darent Valley Hospital in Kent, England present the outcomes of patients undergoing keyhole bowel surgery over a five year period.

The results covered 238 patients over five years of whom 144 had a CardioQ-ODM and 94 did not. The CardioQ-ODM group of patients was found to have been generally sicker and higher risk prior to surgery yet still did better on the following bases than those fitter, lower risk patients denied the CardioQ-ODM:

Lower hospital stay (7 days vs 9)
Lower mortality (1 patient vs 3)
Lower major complications (6 vs 31)
Lower total complications (20 vs 43)
Lower operative time (162 minutes vs 180)

And yet still the sp is dragged down by this topsey turvy non sensical market.
If Deltex found the secret of internal life the bl**dy sp would drop.

No news out and yet sp down 20%. This is scary.

CardioQ-ODM reduces lengths of stay in Spain by six days.

Dr Ramirez, the lead colorectal surgeon from Hospital General Universitario Zaragoza, reported that the average (mean) length of stay had been reduced by six days per patient. After the introduction of CardioQ-ODM as part on an enhanced recovery protocol, patients were discharged after six days, whereas previously they had stayed in hospital for twelve days. A draft health technology assessment by this Agency, based on results from UK randomised controlled trials, indicated that using the CardioQ-ODM would save 900 per patient, reduce mortality rates and significantly reduce complications: the draft conclusions, although contingent on outcomes from the above audit, were already assessed as 'robust'.

So hospital stays reduced by 50% with the huge monetary saving that that entails, this is yet another NO BRAINER. What the hell is stopping this share zooming upwards like a Nov 5th rocket, instead of dropping like a damp squib.

Looks like I'm talking to myself here.
Getting lonely. Anyone out there or am I the only Deltex shareholder left on MoneyAm.

I'm still in this one greekman, haven't posted for a while because it's the same 'ol same 'ol, every trial has shown the massive benefits of DEMG's products. Sales will be the catalyst for the sp, and I have no doubt over the coming months/years this will be a huge success, as with most aim co's, we just need patience.
2517

Hi George,

Thought you might still be about. Agree it's more of the same.
Never needed so much patience with a share. As you rightly say, sales are all that really matter (catalyst for the sp).

Cheers Greek.

Invitation to visit Chichester facility: Tuesday 25 November 2008

Unable to attend myself, but no doubt someone on here will attend and we will see some feedback in a few weeks.

I won't be there either, but a good opportunity for management to encourage visitors to insist on the use of Cardio Q etc, when having operations.
2517

Deltex Medical Group
Share Price; 9.88 p
Market Cap; 9.9m
(DEMG.L)
NB Higher risk as pre-profitability

There is only one technology of choice
If you, as does the author of this comment, consider that the guided fluid management in patients undergoing surgery will become a 'Standard of Care', there is only, at present, one (trial) proven technology in the operating theatre (OT). That is the Group's Oesophageal Doppler Monitor (ODM). As far as the author is aware, no other technology has been (trial) proven to give positive results in the OT. There may be in the future, as LiDCO (London AIM: LID), another UK company, has launched LiDCOrapid for use in the OT, but as it has only recently been launched there is (obviously) not yet any clinical data.

Result of Spanish Trials
At the Congreso Nacional de Cirugia in Madrid, Dr Ramirez, the lead colorectal surgeon from Hospital General Universitario Zaragoza, reported the first findings of the eleven hospitals to have collated data on the impact of introducing CardioQ-ODM as part of an enhanced recovery programme in colorectal surgery. The result were that the average (mean) length of stay had been reduced to six days per patient, whereas previously they had stayed in hospital for twelve days. The results of the audit are being studied by representatives of the Entralgo Agency, which makes recommendations to the Spanish healthcare system about the clinical and cost effectiveness of medical innovations. A previous draft health technology assessment by this Agency indicated that using the CardioQ-ODM would save EUR900 per patient, reduce mortality rates and significantly reduce complications: the draft conclusions, although contingent on outcomes from the above audit, were already assessed as "robust".

Andy Hill, DEMG chief executive, made the following comment with which we are in full agreement.
"These results confirm that we have created a major opportunity to establish a very large, high quality business in Spain. The country's leading surgeons are recommending new packages of care with ODM as the key single innovation and they are already looking beyond colorectal surgery to other types of major surgery. The Spanish government agencies that determine funding priorities have been involved throughout the audit and should now be able to finalise their positive draft health technology assessment and recommend ODM as a standard of care."

Conclusion
We consider that the (not unexpected) results from Spain will lead to major adoption in that country and is further verification of the results of using the ODM. There appears to be a groundswell of opinion that the use of the ODM is by far the most accurate method of managing patients. We, therefore, consider that Deltex is the company of choice for investors wishing to be involved in this technology. Although the market is huge, current market penetration is very low. But the catalysts for widespread adoption now look to be in place. We reiterate our Buy opinion especially given the recent weakness in the share price. We still see the share price multiplying over the medium term and the current market capitalisation is both very small in relation to its potential and its peer group given its better technology and higher growth rate.

Barack Obama has stated that one of his priorities is to reduce the cost of health care in the USA. He wants to cut waste and the cost of all procedures where possible. This will obviously have adverse effects on several arms of health care whilst giving an opportunity for others to increase business/profits.
Drug companies, private hospitals and possibly private health insurance funding, via insurance premiums could suffer.
Deltex could be one of the big winner, especially when/if pressure is put on heath care providers and health insurance companies to lower pricers.
Lets just hope that this is another lever which Deltex can use to open doors.

Barclay's bought almost 5m shares last week.
2517

And their holdings have increased from 35,000 to 5,014,663
Previous holding % Below notifiable % to 5%.

Hopefully we will see more institutions buying, after the invitation to visit Deltex's Chichester facility on Tuesday 25 November 2008, as no doubt those with significant holdings such as institutions will attend.